Axicabtagene ciloleucel (axi-cel) CAR-T — single infusion after lymphodepletion
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-CAR-T-AXICEL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Notes
ZUMA-1 (r/r DLBCL, ≥2 prior lines): ORR ~83%, CR ~58%, durable ~40% at 5-year follow-up. ZUMA-7 expanded indication to 2L for primary- refractory or early-relapse (<12 mo) DLBCL: superior EFS vs salvage chemo + autoSCT. Centre must be FACT/JACIE/REMS-accredited. Boxed warnings: CRS, ICANS, secondary T-cell malignancy (FDA 2024). Plan bridging therapy + caregiver-presence-for-4-weeks-post-infusion as standard. Tisagenlecleucel (Kymriah) and lisocabtagene maraleucel (Breyanzi) are alternative CD19 CAR-T products — separate Regimen entities (future).
Used By
Indication
IND-DLBCL-3L-AXICEL-CART- IND-DLBCL-3L-AXICEL-CART
Regimen
REGIMEN-LISOCEL-DLBCL-3L- Lisocabtagene maraleucel (liso-cel) CAR-T for r/r LBCL ≥3L (TRANSCEND NHL 001)